Page 1

PLX PHARMA INC . PLX Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update November 12 , 2021 Results demonstrate strong execution of initial phase of VAZALORE commercial launch , including shipments to 30,000+ stores nationwide and e - commerce sites -- ΤΗ -- Reported net revenue of $ 6.6 million in third quarter 2021 reflecting initial sales of VAZALORE -- -- Third quarter 2021 net loss was ( $ 0.80 ) per share and adjusted non - GAAP net loss per share of ( $ 0.37 ) -- - Early feedback received from consumers and healthcare professionals is very positive -- SPARTA , N.J. , Nov. 12 , 2021 ( GLOBE NEWSWIRE ) PLX Pharma Inc. ( NASDAQ : PLXP ) ( “ PLx " or the " Company " ) , is a commercial - stage drug delivery platform technology company focused on its clinically - validated and patent - protected PLxGuard ™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs . The Company , with its lead products VAZALORETM 325 mg and VAZALORETM 81 mg liquid - filled aspirin capsules ( referred to together as " VAZALORE " ) , announced today certain financial and operational results for the three and nine months ended September 30 , 2021 . Highlights of , and certain events during and subsequent to , the third quarter of 2021 include : -- • Extensive VA LORE commercial launch activities under way : o Successfully supplied three stock keeping units ( " SKUs " ) of VAZALORE into more than 30,000 retail drugstores , supermarkets , mass merchandisers and e - commerce sites nationwide ; o Deployed a cardiovascular specialty field force to engage with healthcare professionals at leading heart / stroke hospitals and affiliated clinical practices ; o Launched a national media television campaign to raise awareness among providers and consumers ; o Implemented a nationwide pharmacist outreach campaign including email alerts and education kits with information and coupon incentives ; o Continue to receive very positive feedback from consumers and healthcare providers about the benefits of VAZALORE ; • Reported third quarter 2021 revenue of $ 6.6 million and a net loss of ( $ 0.80 ) per basic and diluted share ; adjusted non - GAAP net loss was ( $ 0.37 ) per basic and diluted share ; • Preliminary results of study titled , Pharmacokinetic and Pharmacodynamic Profile of PL - ASA , a Novel Phospholipid - Aspirin Complex Liquid Formulation , Compared to Enteric - coated Aspirin at an 81 mg Dose - Results from a Prospective , Randomized Crossover Study ( F. Franchi et al . ) , were included in a virtual poster presentation during the Transcatheter Cardiovascular Therapeutics Meeting of the Cardiovascular Research Foundation ( TCT 2021 ) in Orlando , FL .; and • Cardiovascular thought leaders held a virtual town hall meeting on October 29 , 2021 titled " Should You Stop ( or Start ) Aspirin ? Ask Your Doctor " as a public health service for patients to help clarify the continued critical role of aspirin in secondary prevention . " We remain focused on executing our VAZALORE commercial strategy with retailers , professionals and consumers , " said Natasha Giordano , Chief Executive Officer of PLx . " The overwhelmingly positive feedback we have received strengthens our confidence in the potential of this brand , " stated Natasha Giordano , Chief Executive Officer of PLx . " Key thought leaders in the field have been pro - actively engaged in clarifying the foundational role of aspirin in secondary prevention of cardiovascular disease . Also , the availability of new scienti fi c data on VAZALORE , which is consistent with previous studies that supported the approvals of VAZALORE 81 mg and 325 mg , continues to demonstrate that VAZALORE delivers fast , reliable absorption that patients depend on to help prevent another heart attack or clot - related stroke , " concluded Giordano . Third Quarter 2021 Financial Highlights Total revenues for the third quarter of 2021 were $ 6.6 million , compared to no revenue in the third quarter of 2020 and reflected the launch of VAZALORE 81 mg and 325 mg dose strengths with initial distribution to US retail channels . Net sales were led by 81 mg dose strength ( consisting of two SKUs ) , which represented approximately two - thirds of total revenues in the third quarter of 2021 . Gross margin of 41 % reflects outsourced manufacturing and packaging costs , shipping and warehousing costs , expenses related to order processing , quality assurance and royalties .